BioNTech SE Sponsored ADR $BNTX Shares Sold by CenterBook Partners LP

CenterBook Partners LP reduced its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 62.4% in the 3rd quarter, Holdings Channel reports. The fund owned 94,333 shares of the company’s stock after selling 156,750 shares during the period. CenterBook Partners LP’s holdings in BioNTech were worth $9,273,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of BNTX. Integrated Wealth Concepts LLC purchased a new position in BioNTech during the 2nd quarter valued at about $39,000. Farther Finance Advisors LLC increased its holdings in shares of BioNTech by 31.5% in the 3rd quarter. Farther Finance Advisors LLC now owns 493 shares of the company’s stock valued at $48,000 after purchasing an additional 118 shares during the period. Quintet Private Bank Europe S.A. lifted its position in shares of BioNTech by 232.8% in the third quarter. Quintet Private Bank Europe S.A. now owns 1,917 shares of the company’s stock worth $188,000 after purchasing an additional 1,341 shares in the last quarter. Quantum Portfolio Management LLC purchased a new stake in shares of BioNTech in the first quarter worth approximately $203,000. Finally, Vise Technologies Inc. acquired a new stake in shares of BioNTech during the third quarter worth approximately $228,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Wall Street Zen raised shares of BioNTech from a “sell” rating to a “hold” rating in a research report on Saturday. Bank of America reaffirmed a “buy” rating on shares of BioNTech in a research note on Wednesday. Argus assumed coverage on BioNTech in a report on Thursday, October 8th. They set a “hold” rating for the company. BMO Capital Markets lowered BioNTech from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $128.00 to $105.00 in a report on Tuesday, September 8th. Finally, Wells Fargo & Company reduced their price objective on BioNTech from $140.00 to $125.00 and set an “overweight” rating for the company in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $123.60.

Insider Buying and Selling

In other news, CEO Ugur Sahin sold 36,209 shares of the stock in a transaction on Friday, October 9th. The shares were sold at an average price of $95.37, for a total transaction of $3,453,252.33. Following the transaction, the chief executive officer owned 36,209 shares in the company, valued at $3,453,252.33. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 807,209 shares of company stock valued at $79,246,837 over the last ninety days. Insiders own 19.20% of the company’s stock.

BioNTech Stock Up 1.9%

NASDAQ:BNTX traded up $1.65 during mid-day trading on Friday, reaching $87.51. The stock had a trading volume of 724,157 shares, compared to its average volume of 1,124,157. The business’s 50 day moving average is $94.66 and its 200 day moving average is $96.70. BioNTech SE Sponsored ADR has a fifty-two week low of $79.52 and a fifty-two week high of $124.00. The stock has a market cap of $22.13 billion, a P/E ratio of -12.78 and a beta of 1.28. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The business had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. BioNTech’s revenue was down 59.5% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.60) EPS. As a group, sell-side analysts predict that BioNTech SE Sponsored ADR will post -6.38 earnings per share for the current year.

BioNTech Profile

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing medicines and vaccines based on messenger RNA and other immunotherapy technologies. The company’s research programs address cancer, infectious diseases, and other serious medical conditions.

BioNTech’s oncology portfolio includes individualized and off-the-shelf cancer immunotherapies, including mRNA-based treatments, cell therapies, antibody-based therapies, and immune-modulating approaches. Its infectious-disease activities include vaccine programs developed through proprietary platforms and collaborations.

In collaboration with Pfizer, BioNTech developed Comirnaty, an mRNA-based COVID-19 vaccine.